J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short

Key TakeawaysJohnson & Johnson's fourth quarter sales met estimates, while net income fell short.After adjusting for one-time costs like acquisitions, the drug and medical device maker's adjusted profits beat estimates.The company's projections for sales during the 2025 fiscal year also came in short of current analyst estimates. Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming ...